AU2003216502B2 - Prevention of recurrence and metastasis of cancer - Google Patents
Prevention of recurrence and metastasis of cancer Download PDFInfo
- Publication number
- AU2003216502B2 AU2003216502B2 AU2003216502A AU2003216502A AU2003216502B2 AU 2003216502 B2 AU2003216502 B2 AU 2003216502B2 AU 2003216502 A AU2003216502 A AU 2003216502A AU 2003216502 A AU2003216502 A AU 2003216502A AU 2003216502 B2 AU2003216502 B2 AU 2003216502B2
- Authority
- AU
- Australia
- Prior art keywords
- tumor
- virus
- subject
- cells
- herpes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36113202P | 2002-03-01 | 2002-03-01 | |
| US60/361,132 | 2002-03-01 | ||
| PCT/US2003/006519 WO2003073918A2 (en) | 2002-03-01 | 2003-03-03 | Prevention of recurrence and metastasis of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003216502A1 AU2003216502A1 (en) | 2003-09-16 |
| AU2003216502B2 true AU2003216502B2 (en) | 2008-04-10 |
Family
ID=27789076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003216502A Ceased AU2003216502B2 (en) | 2002-03-01 | 2003-03-03 | Prevention of recurrence and metastasis of cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050255085A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1487983A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005519091A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003216502B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2476724A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003073918A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| GB0326798D0 (en) * | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| JP2005336094A (ja) * | 2004-05-26 | 2005-12-08 | Akikimi Nakao | 変異単純ヘルペスウイルスからなる転移性乳癌および再発性乳癌の治療剤 |
| US8986672B2 (en) * | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| DK3184641T3 (da) | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
| ES2796488T3 (es) * | 2016-04-08 | 2020-11-27 | Krystal Biotech Inc | Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel |
| EP3426272A4 (en) | 2016-04-26 | 2020-03-04 | Salk Institute for Biological Studies | ONCOLYTIC HSV-1 VIRUS THERAPIES WITH SPECIFIC KILLING OF OLD-DEPENDENT CARCINOMAS |
| MX2020000993A (es) | 2017-07-26 | 2020-07-22 | Oncorus Inc | Vectores virales oncolíticos y usos de estos. |
| WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| EP3856914A1 (en) | 2018-09-26 | 2021-08-04 | Krystal Biotech, Inc. | Compositions and methods for the treatment of skin diseases |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| CN113454105A (zh) | 2019-02-08 | 2021-09-28 | 克里斯托生物技术股份有限公司 | 用于递送cftr多肽的组合物和方法 |
| IL307350A (en) | 2021-04-02 | 2023-11-01 | Krystal Biotech Inc | Viral vectors for cancer treatment |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001091789A2 (en) * | 2000-06-01 | 2001-12-06 | Sloan-Kettering Institute For Cancer Research | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162231A (en) * | 1989-10-25 | 1992-11-10 | Cole Dean A | Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung |
| US5328688A (en) * | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) * | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| CA2132976C (en) * | 1992-03-31 | 2003-12-30 | Bernard Roizman | Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis) |
| US20020010144A1 (en) * | 1994-04-29 | 2002-01-24 | Robert Sobol | Enhancing the sensitivity of tumor cells to therapies |
| US6139834A (en) * | 1994-06-23 | 2000-10-31 | Georgetown University | Replication-competent Herpes simplex virus mediates destruction of neplastic cells |
| US5585096A (en) * | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US6403370B1 (en) * | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US6406861B1 (en) * | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
| EP1150696B1 (en) * | 1999-02-05 | 2006-05-10 | Arch Development Corporation | Genetically engineered herpes virus for the treatment of tumours |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6764675B1 (en) * | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| US7064111B1 (en) * | 1999-10-05 | 2006-06-20 | Georgetown University | Use of soluble costimulatory factor for tumor immuno-gene therapy |
| EP1381280B1 (en) * | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Viral vectors and their use in therapeutic methods |
-
2003
- 2003-03-03 AU AU2003216502A patent/AU2003216502B2/en not_active Ceased
- 2003-03-03 JP JP2003572444A patent/JP2005519091A/ja active Pending
- 2003-03-03 WO PCT/US2003/006519 patent/WO2003073918A2/en not_active Ceased
- 2003-03-03 EP EP03743747A patent/EP1487983A4/en not_active Withdrawn
- 2003-03-03 CA CA002476724A patent/CA2476724A1/en not_active Abandoned
- 2003-03-03 US US10/505,375 patent/US20050255085A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001091789A2 (en) * | 2000-06-01 | 2001-12-06 | Sloan-Kettering Institute For Cancer Research | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
Non-Patent Citations (1)
| Title |
|---|
| Wong, R. J. et al., 2001, Human Gene Therapy, 12: 253-256 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050255085A1 (en) | 2005-11-17 |
| CA2476724A1 (en) | 2003-09-12 |
| EP1487983A4 (en) | 2007-08-15 |
| AU2003216502A1 (en) | 2003-09-16 |
| EP1487983A2 (en) | 2004-12-22 |
| WO2003073918A2 (en) | 2003-09-12 |
| JP2005519091A (ja) | 2005-06-30 |
| WO2003073918A3 (en) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3726841B2 (ja) | 複製能力のある単純ヘルペスウイルスは新生細胞の破壊を媒介する | |
| JP3865319B2 (ja) | 腫瘍または細胞特異的な単純ヘルペスウイルスの複製 | |
| JP5078195B2 (ja) | 腫瘍治療を目的とするヘルペスベクターの使用 | |
| Fernandez et al. | Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease | |
| Herrlinger et al. | Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector | |
| Campadelli‐Fiume et al. | Rethinking herpes simplex virus: the way to oncolytic agents | |
| Wong et al. | Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases | |
| US20050255085A1 (en) | Prevention of recurrence and metastasis of cancer | |
| EP0514603B1 (en) | Viral mediated destruction of neoplastic cells | |
| US6699468B1 (en) | Replication-competent herpes simplex virus mediates destruction of neoplastic cells | |
| Adusumilli et al. | Imaging and therapy of malignant pleural mesothelioma using replication‐competent herpes simplex viruses | |
| US6774119B1 (en) | Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells | |
| JP2003501445A (ja) | 外来遺伝子を発現するヘルペス単純ウイルスおよびそれによる癌の治療方法 | |
| US6139834A (en) | Replication-competent Herpes simplex virus mediates destruction of neplastic cells | |
| Saha et al. | Viral oncolysis of glioblastoma | |
| US20040151697A1 (en) | Replication-competent herpes simplex virus mediates destruction of neoplastic cells | |
| WO2003073919A2 (en) | Treatment of metastatic institute for cancer | |
| WO2023081348A1 (en) | Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells | |
| Gaston et al. | Engineered herpes simplex virus vectors for antitumor therapy and vaccine delivery | |
| Todo et al. | Development of oncolytic replication-competent herpes simplex virus vectors: the G207 paradigm | |
| Price et al. | Herpes Simplex Virus 1 for Cancer Therapy | |
| Baird | Development of a Novel Model for Exploring the Role of Regulatory T-cells in Oncolytic HSV Cancer Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |